Ashkan Shoamanesh: Should Intracranial Hemorrhage Survivors with AFib Receive Anticoagulation?
Ashkan Shoamanesh, Associate Professor of Medicine (Neurology), Marta and Owen Boris Chair in Stroke Research and Care at McMaster University, shared on LinkedIn:
”Should intracranial hemorrhage (ICrH) survivors with atrial fibrillation receive anticoagulation?
If so: under which clinical circumstances?, after what time interval?, with what strategies to mitigate ICrH recurrence risk? and what is the level of supporting evidence?
These are common yet challenging questions in stroke practice, with many remaining unresolved.
We address them in detail in our recently published comprehensive review in the European Stroke Organisation Journal.”
Read the full article here.
Article: Oral Anticoagulation following intracranial haemorrhage in patients with atrial fibrillation
Authors: Ashkan Shoamanesh, Catharina JM Klijn, Kevin N Sheth, Roland Veltkamp, Else C Sandset, Charlotte Cordonnier, Rustam Al-Shahi Salman
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 15, 2026, 19:41Looking Beyond Platelet Counts to Quality of Life in ITP – American Society of Hematology
-
Oct 15, 2026, 19:32Markus Gregorio Barbosa: Hepatic VPS35 and Cholesterol Homeostasis
-
Oct 15, 2026, 19:18Emerging Novel Therapies for Hereditary Hemorrhagic Telangiectasia – The Lancet Haematology
-
Oct 15, 2026, 19:04Umberto Pensato: EVT Treatment Effects Across Perfusion Profiles in MeVO Stroke
-
Oct 15, 2026, 18:26Chanakya Nayudu: Presenting My Research at ISTH Congress 2026 in Paris
-
Oct 15, 2026, 18:09Maha Othman: Students Lead World Thrombosis Day 2026 Awareness Events
-
Oct 15, 2026, 17:52Jill de Mol։ Rapamycin Modulates Immune Responses in Aged Atherosclerosis
-
Oct 15, 2026, 17:41Victor Aboyans։ Think About Lipids in VTE
-
Oct 15, 2026, 17:08Babu Mia։ Targeting PPM1D to Eliminate Malignant Stem Cells in Myeloproliferative Neoplasms